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1173-115 Sequential Changes in Indices of Angiogenesis, 
Endothelial Damage/Dysfunction and Thrombogenesis 
in Acute Coronary Syndromes 
Risk Factors and Outcomes by Body Mass Index Group 
Very Obese 
Natali A. Chuna. Gregory Y. Lip, City Hospital, Birmingham, United Kingdom 
Norma Overweight Obese 
I 
Background: Anglogenesis, as measured by vascular endothelial growth factor (VEGF), 
its receptor sFlt-1 and the angiopoietin receptor Tie-P, endothelial dysfunction, measured 
by van Willebrand factor (vWf), and thrombogenesis. measured by tissue factor (TF). 
may be involved in acute coronary syndromes (ACS). Methods: We investigated 
changes in VEGF, sFlt-I, Tie-a, vWf and TF (all ELISA) in 1 IO patients (89 male, mean 
age 61.4~13.lyears) recruited within 24 hours of admission with ACS. Plasma samples 
were obtained at baseline, 2 months and 6 months from admission. Results were com- 
pared to 31 healthy controls (16 male, mean age 59.6+13.0years). Results: Baseline lev- 
els of vWf and Fit-1 were significantly higher in patients compared to controls (table 1). 
There ware significant changes in vWf, VEGF and Tie-2 over 6 months. Six month levels 
of vWf were comparable to control levels, but sFIt-1 decreased to below control levels 
(p= 0.02). The change (baseline-6 months) in angiogenic indices correlated with each 
other (IVEGF and ATie- Spearman r=O.59, p<O.OOl; AFlt-1 and ATie- rz0.47, 
p=O.OOS). Although changes in TF were not significant, they did correlate with changes in 
sFlt-1 (r=0.29, p=O.O37). Conclusions: Acute cardiac ischaemia results in significant 
changes in levels of angiogenlc and endothelial markers over the subsequent 6 months, 
which may have implications for the pathophysiology of ACS. 
N= 4071 6711 3072 1217 
BMI c=24.9 25.0-29.9 30.0-34.9 >=35.0 
Age (Median) 62 60 57 55 
Diabetes (%) 12 17 23 33 
MVDisease (%) 54 55 58 53 
30-Day Mortality OR 0.66 (0.47, 0.94) 0.61 (0.39, 0.97) 0.89 (0.48, 1.64) 
QO-Day Mortality OR 0.68 (0.51,0.90) 0.60 (0.41, 0.88) 0.70 (0.41, 1.21) 
l-Year Mortality OR 0.74 (0.60, 0.93) 0.68 (0.51, 0.92) 0.97 (0.64, 1.45) 
POSTER SESSION 
Healthy Controls 
VWf 122r23 
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VEGF 59 
(p(Jml) [17-2151 
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Table I 
AYVACS Petients 
Baseline 2 Months 6 Months 
‘I 50+39 124+26 124*28 0.012 
130 100 
[30-2001 (22-I 401 
‘2.7 1.5 
10.6.5.51 [0.5-4.81 
8.5 6.3 
[4.8-15.31 (4.1-8.91 
21 22 
[14-39.5) [15-40.51 
p Value 
100 0.011 
[20-i 401 
‘1.0 0.106 
[0.6-4.41 
7.5 0.011 
[3.9-9.9) 
21.5 0.582 
(14.3-301 
Results expressed as meankstandard deviation or median [interquartile range] and 
analysed by RMANOVA or Friedman’s Test. *p<O.O5 compared to controls 
1173-116 Moderate Obesity Is Associated With Setter 
Intermediate-Term Survival in Acute Coronary 
Syndromes: Results From the SYMPHONY and 2nd 
SYMPHONY Clinical Trials 
Eric L. Eisenstein, Darren K. McGum?, Manjushri V. Bhapkar, David F. Kong, Robeti M. 
Califf, L Kristin Newby, Duke Clinical Research Institute, Durham, NC, University of 
Texas Southwestern Medical Center, Dallas, TX 
Introduction: Obesity is a risk factor for coronary artery disease. However, its indepen- 
dent effect on intermediate-term (<= 1 year) mortality following acute coronary syn- 
dromes (ACS) has not been quantified. Hypothesis: We assessed the hypothesis that 
increasing body mass index (BMI) was associated wth greater risk-adjusted mortality at 
30-days, go-days, and l-year in post-ACS patients (pts). Methods: We used data from 
15,904 pts in 37 countries. Underweight pts (BMI < 18.5, n=833) were excluded. The 
remaining pts were grouped using National Institutes of Health BMI categories: Normal, 
Overweight. Obese, and Very Obese. Results: Increasing BMI was associated with 
younger age. multiple co-morbiditles, and greater use of cardiac medications and proce- 
dures, but no difference in multi-vessel (MV) coronary artery disease or estimates of sys- 
tolic function. Normal weight pts had higher unadjusted intermediate-term mod&y than 
other BMI groups. After adjusting for differences in baseline characteristics, oveweight 
and obese pts had lower intermediate term mortality than the normal weight and very 
obese. BMI group adjusted odds ratios (OR) with 95% confidence intervals relative to 
normal weight pts are shown in the table below. Conclusion: Overweight and Obese 
post-ACS pts have better intermediate-term survival than the Normal weight and Very 
Obese. However, the effect of elevated BMI on longer-term survival (a 1 year) in this 
population is not known. 
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1191-27 Excessive Hospital and One-Year Mortality in Diabetics 
Compared to Nondiabetics With Non-ST Elevation 
Myocardial Infarction in Clinical Practice: Results of the 
ACOS-Registry 
Anselm K. Gitt, Rudolf Schiele, Harm Wienbergen, St&en Schneider, Tobias Hew, 
Martin G. Gottwik, Jochen Senges, ACOS-Study-Group, Herzzentrum Ludwigshafen, 
Ludwigshafen, Germany, Klinikum Nuemberg Sued, Nuemberg. Germany 
Background: Diabetics with ST-elevation myocardial infarction have an impaired hospital 
and longterm prognosis. Little is known about the influence of diabetes on treatment and 
outcome of patients with non-ST-elevation myocardial infarction (NSTEMI) in climcal 
practice. 
Methods: Since June 2000 consecutive pts with acute coronary syndromes (ACS) have 
been enrolled into the ACOS-Registry in 154 hospitals in Germany. We analysed the 
impact of diabetes on hospital and l-year outcome in patients with NSTEMI. 
Results: Out of 12154 consecutive patients with ACS, 4954 (41%) presented with 
NSTEMI, 1567 of these patients (32%) were diabetics. The diabetics were older and 
already had prior MI more often. They received PCI and GP Ilb/llla less often than non- 
diabetics. Diabetics with NSTEMI had a significantly higher hospital and longterm mortal- 
IV than non-diabetics. 
After correction for differences in baseline characteristics and treatment diabetes 
remained a strong predictor of hospital (OR 1.52, 1 .I 7-l .97) and longterm mortality (OR 
2.39, 1.66-3.41) after NSTEMI Conclusion: Diabetics with NSTEMI do receive PCI and 
adjunctive treatment wtth GP Ilb/llla antagonists less often than non-diabetics. In consec- 
utive patients with NSTEMI, diabetes was associated with a relative increase in odds for 
hospital mortality by 52% and for l-year mortality by 139%. 
Age (years) 
Male Gender 
Prior Ml 
PCI 
GP Ilb/llla 
Hospital Mortality 
Diabetics (n=l,567) 
72 
57 % 
21.3% 
33.5 % 
29.5 % 
6.3 % 
Non-Diabetics (n=3,387) p 
68 co.01 
69 % <O.Ol 
16.1 % <O.Ol 
45.5 % <O.Ol 
35.5 % <O.Ol 
4.6 % <O.Ol 
1 -Year-Mortality 
1191-26 
14.1 % 5.9 % co.01 
Injection of Monteplas‘e Prior to Percutaneous Coronary 
Intervention Maintains Left Ventricular Function and 
Prevents Lefl Ventricular Remodeling in Acute 
Myocardlal Infarction Combining Monteplase With 
Angioplasty: COMA Trial 
lsao Yaquchi Teruo Inoue, Ryoichi Nishiki, Junichiro Watanabe, Kei Takizawa, 
Yoshihiko Sakai. Kan Takayanagi, Shigenori Morooka, Koshigaya Hospltal, Dokkyo 
University School of Medicine, Koshigaya, Japan 
INTRODUCTION & HYPOTHESIS:ln the treatment of AMI, rapid reperfusion of the inf- 
arct-related artery (IRA) is important to improve mortality and the long-term prognosis. 
But there is still controversy over whether we should select thrombolysis or PTCA as the 
method of reperfusion. The Combining Monteplase(a mutant t-PA developed in Japan) 
with Angioplasty (COMA) trial is a prospective, randomized trial for evaluating the effec- 
